home / stock / pgen / pgen quote
Last: | $1.47 |
---|---|
Change Percent: | 0.0% |
Open: | $1.51 |
Close: | $1.47 |
High: | $1.53 |
Low: | $1.46 |
Volume: | 382,097 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.47 | $1.51 | $1.47 | $1.53 | $1.46 | 382,097 | 07-04-2024 |
$1.47 | $1.51 | $1.47 | $1.53 | $1.46 | 382,097 | 07-03-2024 |
$1.49 | $1.54 | $1.49 | $1.54 | $1.44 | 805,806 | 07-02-2024 |
$1.55 | $1.56 | $1.55 | $1.57 | $1.53 | 576,550 | 07-01-2024 |
$1.58 | $1.5 | $1.58 | $1.62 | $1.47 | 1,842,516 | 06-28-2024 |
$1.51 | $1.56 | $1.51 | $1.57 | $1.5 | 690,413 | 06-27-2024 |
$1.55 | $1.65 | $1.55 | $1.67 | $1.54 | 755,482 | 06-26-2024 |
$1.67 | $1.63 | $1.67 | $1.67 | $1.6 | 685,485 | 06-25-2024 |
$1.61 | $1.55 | $1.61 | $1.62 | $1.54 | 655,097 | 06-24-2024 |
$1.54 | $1.55 | $1.54 | $1.59 | $1.54 | 790,389 | 06-21-2024 |
$1.53 | $1.57 | $1.53 | $1.58 | $1.52 | 555,591 | 06-20-2024 |
$1.57 | $1.61 | $1.57 | $1.65 | $1.57 | 701,363 | 06-19-2024 |
$1.57 | $1.61 | $1.57 | $1.65 | $1.57 | 701,363 | 06-18-2024 |
$1.63 | $1.62 | $1.63 | $1.67 | $1.6 | 612,337 | 06-17-2024 |
$1.63 | $1.66 | $1.63 | $1.7 | $1.61 | 601,194 | 06-14-2024 |
$1.7 | $1.67 | $1.7 | $1.74 | $1.63 | 661,203 | 06-13-2024 |
$1.67 | $1.63 | $1.67 | $1.73 | $1.63 | 637,470 | 06-12-2024 |
$1.64 | $1.67 | $1.64 | $1.72 | $1.62 | 611,546 | 06-11-2024 |
$1.7 | $1.63 | $1.7 | $1.7 | $1.62 | 760,864 | 06-10-2024 |
$1.62 | $1.67 | $1.62 | $1.69 | $1.59 | 943,917 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...